Is the key to curing the world’s most challenging diseases hidden in unlocking the power of fragmented biological data?
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
Radiopharmaceuticals have also been the target of large partnership deals, including a recent $140 million partnership ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the pharmaceutical packaging market is set to double in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback